Modern Rheumatology最新文献

筛选
英文 中文
Intrinsic chondrogenic transcriptional marker expression is preserved in rheumatoid arthritis synovial fibroblasts but is negatively associated with methotrexate dose. 类风湿性关节炎滑膜成纤维细胞中保留固有的软骨生成转录标志物表达,但与甲氨蝶呤剂量呈负相关。
IF 2.1 4区 医学
Modern Rheumatology Pub Date : 2026-11-07 DOI: 10.1093/mr/roag096
Satoshi Nakayama, Chisato Kawabata, Hirotaka Kawano, Keita Nishimura
{"title":"Intrinsic chondrogenic transcriptional marker expression is preserved in rheumatoid arthritis synovial fibroblasts but is negatively associated with methotrexate dose.","authors":"Satoshi Nakayama, Chisato Kawabata, Hirotaka Kawano, Keita Nishimura","doi":"10.1093/mr/roag096","DOIUrl":"https://doi.org/10.1093/mr/roag096","url":null,"abstract":"<p><strong>Objectives: </strong>The intrinsic chondrogenic potential of synovial fibroblasts in rheumatoid arthritis remains controversial. We examined transcriptional chondrogenic marker expression in rheumatoid arthritis-derived fibroblast-like synoviocytes and explored associated clinical factors.</p><p><strong>Methods: </strong>Synovial tissues were obtained from patients undergoing total knee arthroplasty. Analyses focused on patients younger than 70 years to reduce age-related confounding. Healthy synovial cells served as controls. Cells underwent pellet culture under chondrogenic stimulation, and type II collagen and aggrecan mRNA expression was quantified. Associations with clinical variables were assessed using correlation and exploratory multivariable analyses with adjustment for multiple testing.</p><p><strong>Results: </strong>Type II collagen and aggrecan expression did not differ between rheumatoid arthritis-derived fibroblast-like synoviocytes and healthy controls. Higher methotrexate dose was significantly associated with reduced type II collagen expression, and this association remained significant after false discovery rate adjustment. Exploratory multivariable analyses demonstrated an association between methotrexate dose and type II collagen expression.</p><p><strong>Conclusions: </strong>Transcriptional chondrogenic marker expression under standardized induction conditions was preserved in rheumatoid arthritis-derived fibroblast-like synoviocytes and was negatively associated with methotrexate dose. These findings support a more nuanced view of synovial fibroblast biology in rheumatoid arthritis, beyond a purely destructive phenotype.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149371226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with skeletal muscle mass in patients with Behçet's disease: An exploratory study. behaperet病患者骨骼肌质量相关因素:一项探索性研究
IF 2.1 4区 医学
Modern Rheumatology Pub Date : 2026-11-07 DOI: 10.1093/mr/roag095
Takahiro Hayashi, Hideyo Tsutsui, Naoki Tomiyama, Hirotoshi Kikuchi, Hajime Kono
{"title":"Factors associated with skeletal muscle mass in patients with Behçet's disease: An exploratory study.","authors":"Takahiro Hayashi, Hideyo Tsutsui, Naoki Tomiyama, Hirotoshi Kikuchi, Hajime Kono","doi":"10.1093/mr/roag095","DOIUrl":"https://doi.org/10.1093/mr/roag095","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the prevalence of low skeletal muscle mass and factors associated with skeletal muscle mass index (SMI) in Japanese outpatients with Behçet's disease (BD), while assessing sarcopenia according to the Asian Working Group for Sarcopenia 2025 criteria.</p><p><strong>Methods: </strong>This cross-sectional study included ambulatory outpatients with BD aged ≥40 years. SMI was measured using multifrequency bioelectrical impedance analysis. Sarcopenia was defined as low SMI with low handgrip strength. Clinical characteristics, physical functions, nutrition- and body composition-related measures, rectus femoris ultrasonography, and laboratory parameters were compared between the low- and normal-SMI groups. Associations with SMI were examined using age- and sex-adjusted and domain-specific multivariable linear regression models.</p><p><strong>Results: </strong>Among 48 patients (mean age: 65.4±11.8 years; 45.8% women), 52.1% had Low SMI, and 10.6% of 47 participants with available SMI and handgrip strength data had sarcopenia. In multivariable analyses, higher SMI remained associated with higher body mass index, greater handgrip strength, larger calf circumference, higher phase angle, and greater rectus femoris muscle thickness.</p><p><strong>Conclusions: </strong>Low skeletal muscle mass is common in BD ambulatory outpatients and is associated with muscle-, nutrition-, and body composition-related measures. However, clear associations with disease activity and current systemic glucocorticoid use were not observed.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149371225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment Patterns of Oral Glucocorticoids in Patients with IgG4-Related Disease: A Real-World Analysis based on a Japanese Claims Database. igg4相关疾病患者口服糖皮质激素的治疗模式:基于日本索赔数据库的现实世界分析
IF 2.1 4区 医学
Modern Rheumatology Pub Date : 2026-11-07 DOI: 10.1093/mr/roag097
Mitsuhiro Kawano, Hirokazu Sato, Masamichi Yamamoto, Nagisa Takashima, Yoshiko Ikawa, Yoshie Hongo, Kazuichi Okazaki
{"title":"Treatment Patterns of Oral Glucocorticoids in Patients with IgG4-Related Disease: A Real-World Analysis based on a Japanese Claims Database.","authors":"Mitsuhiro Kawano, Hirokazu Sato, Masamichi Yamamoto, Nagisa Takashima, Yoshiko Ikawa, Yoshie Hongo, Kazuichi Okazaki","doi":"10.1093/mr/roag097","DOIUrl":"https://doi.org/10.1093/mr/roag097","url":null,"abstract":"<p><strong>Objectives: </strong>To describe the prescribing patterns of oral glucocorticoid and evaluate flares and glucocorticoid-related complications in patients with immunoglobulin G4-related disease.</p><p><strong>Methods: </strong>This retrospective observational study used a Japanese hospital claims database. Patients with a prescription for oral glucocorticoids, a diagnosis of immunoglobulin G4-related disease, and having at least two immunoglobulin G4 measurement tests were included. The index date was defined as the first oral glucocorticoid prescription recorded in the database (Day 0). Patients were followed for up to Day 1460 (4 years).</p><p><strong>Results: </strong>The study included 3,167 patients. The mean dose of oral glucocorticoid was 28.76, 10.71, and 4.12 mg/day on Day 0, 90, and 1095, respectively. At Day 1460, 66.56% of the patients were still receiving oral glucocorticoid therapy and the dose exceeded 5 mg/day in 17.80% of patients. During the follow-up period, 453 patients (14.30%) experienced at least one flare. The incidence rates of hospitalized infections, osteoporotic fractures, and cardiovascular diseases, defined as serious glucocorticoid complications, were 7.46, 0.61, and 1.61 per 100 person-years, respectively.</p><p><strong>Conclusions: </strong>Over half of the patients continued glucocorticoid therapy at 4 years. Glucocorticoid withdrawal strategies could be associated with reducing the long-term glucocorticoid-related toxicity in patients with immunoglobulin G4-related disease.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149371227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of quality indicators for systemic sclerosis patients. 系统性硬化症患者质量指标的制定。
IF 2.1 4区 医学
Modern Rheumatology Pub Date : 2026-11-05 DOI: 10.1093/mr/roag091
Mika Hatano, Nobuyuki Yajima, Utako Kaneko, Shuya Kaneko, Kyoko Tonomura, Ikuko Ueda-Hayakawa, Yasuhito Hamaguchi, Masatoshi Jinnin, Yasushi Kawaguchi, Yoshihito Shima, Hidekata Yasuoka, Masaru Hatano, Masaki Shimizu, Naoki Mugii, Takako Miyamae, Yoshihide Asano
{"title":"Development of quality indicators for systemic sclerosis patients.","authors":"Mika Hatano, Nobuyuki Yajima, Utako Kaneko, Shuya Kaneko, Kyoko Tonomura, Ikuko Ueda-Hayakawa, Yasuhito Hamaguchi, Masatoshi Jinnin, Yasushi Kawaguchi, Yoshihito Shima, Hidekata Yasuoka, Masaru Hatano, Masaki Shimizu, Naoki Mugii, Takako Miyamae, Yoshihide Asano","doi":"10.1093/mr/roag091","DOIUrl":"https://doi.org/10.1093/mr/roag091","url":null,"abstract":"<p><strong>Objectives: </strong>To develop quality indicators for evaluating and improving care for patients with systemic sclerosis.</p><p><strong>Methods: </strong>We developed quality indicators using a modified RAND/University of California Los Angeles Appropriateness Method. A systematic literature review identified candidate items from previous systemic sclerosis quality indicator studies and clinical practice guidelines. A multidisciplinary expert panel of 10 physicians specializing in rheumatology, dermatology, pediatrics and cardiology completed two anonymous rating rounds, with item revision after a web-based panel meeting. One physiotherapist and one patient with systemic sclerosis participated as non-voting observers. Items with a median appropriateness score of 7 or higher and strict agreement were retained.</p><p><strong>Results: </strong>The review identified 86 candidate items from three quality indicator studies and 23 clinical practice guidelines. After first-round rating and discussion, 78 revised items underwent second-round evaluation. Thirty-three indicators met the prespecified selection criteria. The final set covered general management, lung, gastrointestinal, kidney, heart, pulmonary hypertension, vascular, muscle, rehabilitation, and pediatric domains.</p><p><strong>Conclusions: </strong>We developed a 33-item quality indicator set for systemic sclerosis through a structured consensus process. The indicators may support quality assessment and improvement in Japanese clinical practice.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149334538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transitional Care for Juvenile-onset Rheumatic and Musculoskeletal Diseases in Japan: A Web-based Survey of JCR and PRAJ Councillors/Board Members. 日本青少年风湿性和肌肉骨骼疾病的过渡性护理:JCR和PRAJ委员/董事会成员的网络调查。
IF 2.1 4区 医学
Modern Rheumatology Pub Date : 2026-11-05 DOI: 10.1093/mr/roag092
Hidehiko Narazaki, Hiroaki Ida, Shuichi Ito, Hiroaki Umebayashi, Kayoko Kaneko, Yohei Kirino, Masaki Shimizu, Susumu Nishiyama, Toshihiro Matsui, Yuichi Mochida, Nobuyuki Yajima, Masaaki Mori
{"title":"Transitional Care for Juvenile-onset Rheumatic and Musculoskeletal Diseases in Japan: A Web-based Survey of JCR and PRAJ Councillors/Board Members.","authors":"Hidehiko Narazaki, Hiroaki Ida, Shuichi Ito, Hiroaki Umebayashi, Kayoko Kaneko, Yohei Kirino, Masaki Shimizu, Susumu Nishiyama, Toshihiro Matsui, Yuichi Mochida, Nobuyuki Yajima, Masaaki Mori","doi":"10.1093/mr/roag092","DOIUrl":"https://doi.org/10.1093/mr/roag092","url":null,"abstract":"<p><strong>Objective: </strong>To describe transitional care for juvenile rheumatic and musculoskeletal disorders in Japan and identify barriers/facilitators to collaboration between departments and facilities.</p><p><strong>Methods: </strong>We conducted a cross-sectional web-based survey in Japan (19 February-26 April 2025) targeting councillors/board members of the Japan College of Rheumatology and the Paediatric Rheumatology Association of Japan. Fisher's exact tests and odds ratios were used for comparing adult and paediatric rheumatology services, and five major cities and others. Sparse cells were examined using Firth's penalised logistic regression.</p><p><strong>Results: </strong>Of 159 submitted questionnaires, 122 were valid. Over 70% managed transitioned patients in the past 3 years. Respondents perceived that transition-related activity had increased (34.9%), whereas barriers remained unchanged (68.6%). Among adult rheumatology declining transitioned patients, 83.3% reported 'no referral received'. Awareness/ever utilised was 73.3%/24.4% for the Transition Support Guide and 45.3%/23.3% for MIRAI TALK, a patient-held transition communication/support tool for paediatric rheumatic diseases. Paediatrics showed higher awareness and ever utilisation of both tools than adult rheumatology. Preconception care awareness was high, with 68.9% implementation and with significantly less frequent male-targeted counselling in adult rheumatology. Awareness of transitional care support centres was limited (one-third) and lower in adult rheumatology.</p><p><strong>Conclusion: </strong>Among surveyed rheumatology specialists, transition-related activity was perceived to have increased, but referral gaps, low adult-side tool uptake, and limited consultation pathways persist.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149334539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consolidation volume assessed by quantitative computed tomography predicts the prognosis of pneumocystis pneumonia in rheumatic diseases. 定量计算机断层扫描评估实变体积预测风湿疾病肺囊虫性肺炎的预后。
IF 2.1 4区 医学
Modern Rheumatology Pub Date : 2026-11-04 DOI: 10.1093/mr/roag043
Kodai Sakiyama, Ryo Hisada, Mitsutaka Yasuda, Maria Tada, Yotaro Oki, Masanari Sugawara, Yuka Shimizu, Shuhei Shimoyama, Shuhei Takeyama, Tetsuya Horita, Masaru Yoshimura, Michihito Kono, Yuichiro Fujieda, Olga Amengual, Masaru Kato, Tatsuya Atsumi
{"title":"Consolidation volume assessed by quantitative computed tomography predicts the prognosis of pneumocystis pneumonia in rheumatic diseases.","authors":"Kodai Sakiyama, Ryo Hisada, Mitsutaka Yasuda, Maria Tada, Yotaro Oki, Masanari Sugawara, Yuka Shimizu, Shuhei Shimoyama, Shuhei Takeyama, Tetsuya Horita, Masaru Yoshimura, Michihito Kono, Yuichiro Fujieda, Olga Amengual, Masaru Kato, Tatsuya Atsumi","doi":"10.1093/mr/roag043","DOIUrl":"10.1093/mr/roag043","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the prognostic value of quantitative computed tomography (QCT) analysis in pneumocystis pneumonia (PCP) patients with rheumatic diseases, specifically relating abnormal lung volumes (ALV) to major clinical events (MCE).</p><p><strong>Methods: </strong>This multicentre, retrospective study included 83 PCP patients with rheumatic diseases. QCT automatically quantified ALV, categorized into consolidation (≥ -300 HU) and ground-glass opacities (< -300 HU). The primary outcome was MCE, including intubation, intensive care unit admission and death. Logistic regression and survival analyses assessed associations between QCT-derived volumes and MCE.</p><p><strong>Results: </strong>MCE occurred in 17 patients (20%). Patients with MCE had significantly larger consolidation volumes than those without MCE (median, 5.7% vs 0.4%, P < 0.001). Logistic regression analysis identified lactate dehydrogenase, C-reactive protein and beta-D-glucan as risk factors; however, consolidation volume remained independently associated with MCE after adjustment (odds ratio: 1.33, 95% confidence interval 1.11-1.59, P < 0.001). Receiver operating characteristic analysis of consolidation volume for predicting MCE showed an area under the curve of 0.89 (P < 0.001). Kaplan-Meier analysis revealed significantly lower MCE-free survival in patients with consolidation volumes ≥1.4% (P < 0.001; log-rank test).</p><p><strong>Conclusions: </strong>In PCP patients with rheumatic diseases, QCT-derived consolidation volume is a strong predictor of severe outcomes.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1039-1045"},"PeriodicalIF":2.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147949015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing methotrexate intolerance in rheumatoid arthritis: The role of oral-to-subcutaneous switching. 类风湿关节炎患者甲氨蝶呤不耐受的管理:口服到皮下转换的作用。
IF 2.1 4区 医学
Modern Rheumatology Pub Date : 2026-11-04 DOI: 10.1093/mr/roag070
Shin-Ichiro Ohmura
{"title":"Managing methotrexate intolerance in rheumatoid arthritis: The role of oral-to-subcutaneous switching.","authors":"Shin-Ichiro Ohmura","doi":"10.1093/mr/roag070","DOIUrl":"10.1093/mr/roag070","url":null,"abstract":"<p><p>Methotrexate (MTX) remains the anchor drug in the management of rheumatoid arthritis. However, its clinical use is frequently limited by intolerance, leading to dose reduction or discontinuation. In addition, oral MTX exhibits pharmacokinetic limitations, including dose-dependent absorption and reduced bioavailability at higher doses, which may compromise therapeutic efficacy. Subcutaneous (SC) MTX has emerged as a strategy to overcome these limitations by providing more consistent bioavailability and potentially improved tolerability. Evidence suggests that switching from oral-to-SC MTX may improve gastrointestinal intolerance and support treatment persistence, whereas evidence for improved disease control or reduction of serious MTX-related toxicity remains limited. Recent Japanese studies suggest the potential utility of this approach at MTX doses commonly used in Japan, although evidence for the superiority of SC MTX over oral MTX in low-dose settings remains limited. This narrative review summarizes current evidence on MTX intolerance and oral-to-SC route switching in rheumatoid arthritis, with a focus on practical strategies for treatment optimization. Overall, oral-to-SC MTX switching may represent an important option to improve gastrointestinal intolerance and support treatment persistence in patients with rheumatoid arthritis.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"869-875"},"PeriodicalIF":2.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness and safety of sarilumab in polymyalgia rheumatica: A retrospective study of the FIRST registry. Sarilumab治疗风湿性多肌痛的有效性和安全性:FIRST注册的回顾性研究
IF 2.1 4区 医学
Modern Rheumatology Pub Date : 2026-11-04 DOI: 10.1093/mr/roag030
Naoaki Ohkubo, Yusuke Miyazaki, Satoshi Kubo, Ippei Miyagawa, Koshiro Sonomoto, Yoshino Inoue, Yurie Satoh-Kanda, Hiroaki Tanaka, Masanobu Ueno, Atsushi Nagayasu, Takafumi Aritomi, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Kiyotake Yoshioka, Mayu Nishimoto, Kazuki Takahashi, Shingo Nakayamada, Yoshiya Tanaka
{"title":"Effectiveness and safety of sarilumab in polymyalgia rheumatica: A retrospective study of the FIRST registry.","authors":"Naoaki Ohkubo, Yusuke Miyazaki, Satoshi Kubo, Ippei Miyagawa, Koshiro Sonomoto, Yoshino Inoue, Yurie Satoh-Kanda, Hiroaki Tanaka, Masanobu Ueno, Atsushi Nagayasu, Takafumi Aritomi, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Kiyotake Yoshioka, Mayu Nishimoto, Kazuki Takahashi, Shingo Nakayamada, Yoshiya Tanaka","doi":"10.1093/mr/roag030","DOIUrl":"10.1093/mr/roag030","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the effectiveness of sarilumab in patients with polymyalgia rheumatica (PMR) who were clinically assessed as having coexisting rheumatoid arthritis.</p><p><strong>Methods: </strong>Using data from the FIRST registry, a cohort of patients initiating molecular targeted therapy for rheumatoid arthritis, we identified cases from 2003 to April 2024 in which sarilumab was introduced as the first biologic agent and PMR was concurrently diagnosed. As a control group, we selected patients hospitalized for a PMR flare during the same period who received the standard of care without biologic therapy. The primary outcome was the clinical PMR Activity Score at 52 weeks post-treatment initiation.</p><p><strong>Results: </strong>Among 5645 registered cases, 67 patients were identified as having PMR with coexisting rheumatoid arthritis and received sarilumab as their initial biologic therapy. The control group comprised 76 patients treated with conventional therapy alone. The 52-weeks continuation rate of sarilumab was 77.5%, indicating high treatment persistence. At 52 weeks, clinical PMR Activity Score scores decreased in both groups. Logistic regression analysis using low disease activity at 52 weeks as the outcome revealed sarilumab use as a significant predictor. After adjusting for baseline differences using inverse probability weighting based on propensity scores, the sarilumab group showed a significantly greater reduction in the clinical PMR Activity Score compared to the standard of care group.</p><p><strong>Conclusions: </strong>These findings suggest that sarilumab may have the potential to improve disease activity in polymyalgia rheumatica compared to conventional therapy.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1046-1054"},"PeriodicalIF":2.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study. 系统性红斑狼疮患者糖皮质激素减量期间的危险因素和贝利单抗对耀斑的影响:一项多中心应答- sle队列研究
IF 2.1 4区 医学
Modern Rheumatology Pub Date : 2026-11-04 DOI: 10.1093/mr/roag053
Hirofumi Miyake, Akira Onishi, Hideaki Tsuji, Takuya Kotani, Yumiko Wada, Yuji Nozaki, Toshihiko Shiga, Shigeru Iwata, Takao Fujii, Yasuhiro Kato, Eri Itotagawa, Shuji Sumitomo, Hideki Oka, Wataru Yamamoto, Masao Katsushima, Motomu Hashimoto
{"title":"Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study.","authors":"Hirofumi Miyake, Akira Onishi, Hideaki Tsuji, Takuya Kotani, Yumiko Wada, Yuji Nozaki, Toshihiko Shiga, Shigeru Iwata, Takao Fujii, Yasuhiro Kato, Eri Itotagawa, Shuji Sumitomo, Hideki Oka, Wataru Yamamoto, Masao Katsushima, Motomu Hashimoto","doi":"10.1093/mr/roag053","DOIUrl":"10.1093/mr/roag053","url":null,"abstract":"<p><strong>Objectives: </strong>To identify the factors associated with flares after glucocorticoid (GC) reduction in systemic lupus erythematosus (SLE) and to determine whether belimumab (BLM) influences this risk.</p><p><strong>Methods: </strong>Using the ANSWER-SLE cohort, this retrospective, multicentre study enrolled 388 patients with a GC reduction from ≤5 mg/day. The primary outcome was the time to an overall flare (SLE Disease Activity Index 2000 [SLEDAI-2K] increase of ≥3 or a GC escalation). Multivariable Cox models identified factors associated with an overall flare. Propensity score-based matching weights were applied, and weighted Cox models assessed the association between BLM and flare risk.</p><p><strong>Results: </strong>During a 1-year follow-up, 133 overall flares occurred (1-year cumulative incidence 39.9%). A higher clinical SLEDAI (hazard ratio [HR] 1.10, 95% confidence interval [CI] 1.03-1.17), Systemic Lupus International Collaborating Clinics Damage Index (SDI) (HR 1.11, 95% CI 1.01-1.22), and GC dose reduction (HR 1.40, 95% CI 1.15-1.70) were associated with an increased overall flare risk. GC reductions of >1 mg were associated with flare (HR 2.53, 95% CI 1.54-4.15). In the weighted analyses, BLM was not associated with an overall flare (HR 0.83, 95% CI 0.51-1.34).</p><p><strong>Conclusions: </strong>In patients with SLE, carefully tapering GC doses from ≤5 mg/day according to disease activity and organ damage may be important, whereas BLM was not associated with a reduced flare risk.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"972-978"},"PeriodicalIF":2.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148339210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A narrative review of the diagnostic role of muscle biopsy in small- to medium-vessel vasculitis: Consideration of imaging-guided procedures. 对肌肉活检在中小血管炎诊断中的作用的综述:对成像引导程序的考虑。
IF 2.1 4区 医学
Modern Rheumatology Pub Date : 2026-11-04 DOI: 10.1093/mr/roag036
Shin-Ichiro Ohmura
{"title":"A narrative review of the diagnostic role of muscle biopsy in small- to medium-vessel vasculitis: Consideration of imaging-guided procedures.","authors":"Shin-Ichiro Ohmura","doi":"10.1093/mr/roag036","DOIUrl":"10.1093/mr/roag036","url":null,"abstract":"<p><p>Muscle biopsy (MB) remains an important diagnostic option in small- to medium-vessel vasculitis, particularly when other tissue biopsies are non-diagnostic. This narrative review aimed to clarify the diagnostic role of MB, summarize key histopathological features, and evaluate the clinical utility of imaging-guided procedures. A structured literature search of Medline/PubMed (2000-25) identified 10 relevant studies for synthesis. Available evidence indicates that skeletal muscle is a valuable tissue for detecting vasculitic lesions, even in the absence of myalgia or creatine kinase elevation. Reported diagnostic yields vary across studies, reflecting differences in patient selection, biopsy techniques, and imaging use. Higher yields have been reported in imaging-guided procedures, particularly magnetic resonance imaging-guided biopsy. However, evidence is largely derived from small, retrospective, and heterogeneous cohorts. Adequate sampling, including epimysial and perimysial tissue with appropriate staining, is essential to improve diagnostic reliability. In clinical practice, MB should be considered when suspicion of vasculitis persists despite non-diagnostic initial investigations. Magnetic resonance imaging may assist in identifying target biopsy sites and reducing sampling error. Overall, MB demonstrates diagnostic value in clinical practice, although results vary considerably and evidence remains heterogeneous.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"892-901"},"PeriodicalIF":2.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书